CL2004001705A1 - Nucleo esferoide que contiene 6-29% de clorhidrato de venlafaxina, 94-71% de celulosa microcristalina y 0.25-1% de hidroxipropilmetilcelulosa y esferoide que comprende dicho nucleo con un recubrimiento de una mezcla de etilcelulosa e hidroxipropilmet - Google Patents
Nucleo esferoide que contiene 6-29% de clorhidrato de venlafaxina, 94-71% de celulosa microcristalina y 0.25-1% de hidroxipropilmetilcelulosa y esferoide que comprende dicho nucleo con un recubrimiento de una mezcla de etilcelulosa e hidroxipropilmetInfo
- Publication number
- CL2004001705A1 CL2004001705A1 CL200401705A CL2004001705A CL2004001705A1 CL 2004001705 A1 CL2004001705 A1 CL 2004001705A1 CL 200401705 A CL200401705 A CL 200401705A CL 2004001705 A CL2004001705 A CL 2004001705A CL 2004001705 A1 CL2004001705 A1 CL 2004001705A1
- Authority
- CL
- Chile
- Prior art keywords
- spheroid
- nucleus
- chlorhydrate
- microcrystalline cellulose
- venlafaxine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE RELACIONA CON UNA FORMULA POSOLOGICA Y DOSIS UNITARIA DE LA MISMA, DE CLORHIDRATO DE VANLAFAXINA, UN AGENTE ANTIDEPRESIVO, DE LIBERACION PROLONGADA SOBRE 24 HORAS, QUE OFRECE UN CONTROL MEJOR DE LAS CONCENTRACIONES PLASMATICAS QUE EL DE LAS FORMULAS CONVENCIONALES EN TABLETAS QUE DEBEN ADINISTRARSE DOS O MAS VECES AL DIA Y QUE TAMBIEN SE ASOCIA CON UNA INCIDENCIA MENOR DE NAUSEAS Y VOMITOS QUE LAS TABLETAS CONVENCIONALES. EN SU ASPECTO PRIMARIO, ESTA INVENCION OFRECE UN NUCLEO MEJORADO DE LOS ESFEROIDES DE LIBERACION PROLONGADA, QUE COMPRENDE CLORHIDRATOS DE VENLAFAXINA Y CELULOSA MICROCRISTALINA, ES DECIR, SIN EL AGREGADO DE HIDROXIPROPILMETILCELULOSA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96432897A | 1997-11-05 | 1997-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004001705A1 true CL2004001705A1 (es) | 2005-06-03 |
Family
ID=25508423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200401705A CL2004001705A1 (es) | 1997-11-05 | 2004-07-06 | Nucleo esferoide que contiene 6-29% de clorhidrato de venlafaxina, 94-71% de celulosa microcristalina y 0.25-1% de hidroxipropilmetilcelulosa y esferoide que comprende dicho nucleo con un recubrimiento de una mezcla de etilcelulosa e hidroxipropilmet |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1028718B1 (es) |
JP (1) | JP2001521892A (es) |
KR (1) | KR20010031797A (es) |
CN (1) | CN1278165A (es) |
AR (1) | AR014012A1 (es) |
AT (1) | ATE237320T1 (es) |
AU (1) | AU747978B2 (es) |
BG (1) | BG104397A (es) |
BR (1) | BR9813179A (es) |
CA (1) | CA2305242A1 (es) |
CL (1) | CL2004001705A1 (es) |
CO (1) | CO5011060A1 (es) |
CZ (1) | CZ20001659A3 (es) |
DE (1) | DE69813602T2 (es) |
DK (1) | DK1028718T3 (es) |
EA (1) | EA200000487A1 (es) |
EE (1) | EE04577B1 (es) |
ES (1) | ES2196620T3 (es) |
GE (1) | GEP20043198B (es) |
HK (1) | HK1029056A1 (es) |
HR (1) | HRP20000213B1 (es) |
HU (1) | HU225238B1 (es) |
ID (1) | ID26317A (es) |
IL (1) | IL135457A0 (es) |
MA (1) | MA24691A1 (es) |
NO (1) | NO20002126L (es) |
NZ (1) | NZ504460A (es) |
PA (1) | PA8462501A1 (es) |
PE (1) | PE128699A1 (es) |
PL (1) | PL341141A1 (es) |
PT (1) | PT1028718E (es) |
SK (1) | SK6472000A3 (es) |
SV (1) | SV1998000131A (es) |
TR (1) | TR200001232T2 (es) |
TW (1) | TW555568B (es) |
UA (1) | UA77145C2 (es) |
UY (2) | UY25234A1 (es) |
WO (1) | WO1999022724A2 (es) |
ZA (1) | ZA9810081B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1905757A1 (en) * | 1999-04-06 | 2008-04-02 | Sepracor Inc. | Derivatives of Venlafaxine and methods of preparing and using the same |
RU2275191C2 (ru) * | 1999-05-20 | 2006-04-27 | Элан Корпорейшн, Плс | Состоящие из множества частиц фармацевтические составы с контролируемым высвобождением избирательного ингибитора повторного поглощения серотонина |
IL146462A (en) | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
EP1451145A1 (en) * | 2001-12-05 | 2004-09-01 | Wyeth | Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof |
WO2003050074A1 (en) * | 2001-12-13 | 2003-06-19 | Cadila Healthcare Limited | Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof |
AU2002217373A1 (en) * | 2002-01-03 | 2003-07-15 | Lek Pharmaceutical And Chemical Company D.D. | Controlled release pharmaceutical formulation containing venlafaxine |
US20030190351A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon Bv | Extended release venlafaxine formulations |
AU2003226751A1 (en) | 2002-03-28 | 2003-10-13 | Synthon B.V. | Low water-soluble venlafaxine salts |
EP1487429A2 (en) * | 2002-03-28 | 2004-12-22 | Synthon B.V. | Compositions of venlafaxine base |
EP1485344A1 (en) | 2002-03-28 | 2004-12-15 | Synthon B.V. | Venlafaxine besylate |
FR2845289B1 (fr) | 2002-10-04 | 2004-12-03 | Ethypharm Sa | Spheroides, procede de preparation et compositions pharmaceutiques. |
CA2415154C (en) * | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
DE10350194B4 (de) * | 2003-10-28 | 2005-11-10 | Bioplanta Arzneimittel Gmbh | Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen |
TW200503670A (en) * | 2003-03-28 | 2005-02-01 | Sandoz Ag | Venlafaxine compositions |
DK1502587T3 (da) * | 2003-07-30 | 2007-01-02 | Pharmathen Sa | Formulering med vedvarende frigivelse af venlafaxinhydrochlorid |
HUP0303382A2 (hu) * | 2003-10-10 | 2005-08-29 | EGIS Gyógyszergyár Rt. | Venlafaxin-hidroklorid-tartalmú pelletek |
PT1711169E (pt) | 2004-02-04 | 2007-07-23 | Alembic Ltd | Minicomprimidos revestidos de libertação prolongada de cloridrato de venlafaxina. |
US7776358B2 (en) | 2004-07-22 | 2010-08-17 | Synthon Ip Inc. | Extended release venlafaxine besylate tablets |
JP5349290B2 (ja) * | 2006-04-03 | 2013-11-20 | オディディ,イサ | 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法 |
WO2007129329A2 (en) * | 2006-05-08 | 2007-11-15 | Jubilant Organosys Limited | Extended release pharmaceutical formulation comprising venlafaxine hydrochloride |
CN102772390B (zh) * | 2012-08-16 | 2014-01-08 | 乐普药业股份有限公司 | 一种盐酸文拉法辛缓释胶囊及其制备方法 |
FR3080278B1 (fr) * | 2018-04-11 | 2021-04-30 | Ghs Patents Ltd | Procede de fabrication d'un spheroide de cannabidiol |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1561204A (en) * | 1977-06-01 | 1980-02-13 | Ici Ltd | Sustained release pharmaceutical composition |
US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
ZA97976B (en) * | 1996-04-05 | 1997-08-18 | Alza Corp | Uniform drug delivery theraphy. |
-
1998
- 1998-03-11 UA UA2000063197A patent/UA77145C2/uk unknown
- 1998-10-30 PA PA19988462501A patent/PA8462501A1/es unknown
- 1998-11-02 MA MA25330A patent/MA24691A1/fr unknown
- 1998-11-03 GE GEAP19985388A patent/GEP20043198B/en unknown
- 1998-11-03 PL PL98341141A patent/PL341141A1/xx not_active Application Discontinuation
- 1998-11-03 JP JP2000518658A patent/JP2001521892A/ja active Pending
- 1998-11-03 AT AT98956487T patent/ATE237320T1/de not_active IP Right Cessation
- 1998-11-03 CA CA002305242A patent/CA2305242A1/en not_active Abandoned
- 1998-11-03 BR BR9813179-6A patent/BR9813179A/pt not_active Application Discontinuation
- 1998-11-03 IL IL13545798A patent/IL135457A0/xx unknown
- 1998-11-03 KR KR1020007004865A patent/KR20010031797A/ko not_active Application Discontinuation
- 1998-11-03 WO PCT/US1998/023338 patent/WO1999022724A2/en not_active Application Discontinuation
- 1998-11-03 EA EA200000487A patent/EA200000487A1/ru unknown
- 1998-11-03 NZ NZ504460A patent/NZ504460A/xx unknown
- 1998-11-03 EE EEP200000212A patent/EE04577B1/xx not_active IP Right Cessation
- 1998-11-03 CZ CZ20001659A patent/CZ20001659A3/cs unknown
- 1998-11-03 TR TR2000/01232T patent/TR200001232T2/xx unknown
- 1998-11-03 CN CN98810881A patent/CN1278165A/zh active Pending
- 1998-11-03 SK SK647-2000A patent/SK6472000A3/sk unknown
- 1998-11-03 EP EP98956487A patent/EP1028718B1/en not_active Revoked
- 1998-11-03 TW TW086102797A patent/TW555568B/zh not_active IP Right Cessation
- 1998-11-03 DK DK98956487T patent/DK1028718T3/da active
- 1998-11-03 ES ES98956487T patent/ES2196620T3/es not_active Expired - Lifetime
- 1998-11-03 AU AU13003/99A patent/AU747978B2/en not_active Ceased
- 1998-11-03 PT PT98956487T patent/PT1028718E/pt unknown
- 1998-11-03 ID IDW20000834A patent/ID26317A/id unknown
- 1998-11-03 HU HU0004287A patent/HU225238B1/hu not_active IP Right Cessation
- 1998-11-03 DE DE69813602T patent/DE69813602T2/de not_active Revoked
- 1998-11-03 CO CO98064480A patent/CO5011060A1/es unknown
- 1998-11-04 SV SV1998000131A patent/SV1998000131A/es not_active Application Discontinuation
- 1998-11-04 ZA ZA9810081A patent/ZA9810081B/xx unknown
- 1998-11-04 PE PE1998001045A patent/PE128699A1/es not_active Application Discontinuation
- 1998-11-04 AR ARP980105563A patent/AR014012A1/es unknown
- 1998-11-05 UY UY25234A patent/UY25234A1/es not_active IP Right Cessation
-
1999
- 1999-09-03 UY UY25692A patent/UY25692A1/es not_active IP Right Cessation
-
2000
- 2000-04-13 HR HR20000213A patent/HRP20000213B1/xx not_active IP Right Cessation
- 2000-04-26 NO NO20002126A patent/NO20002126L/no not_active Application Discontinuation
- 2000-05-04 BG BG104397A patent/BG104397A/xx unknown
- 2000-12-21 HK HK00108358A patent/HK1029056A1/xx not_active IP Right Cessation
-
2004
- 2004-07-06 CL CL200401705A patent/CL2004001705A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004001705A1 (es) | Nucleo esferoide que contiene 6-29% de clorhidrato de venlafaxina, 94-71% de celulosa microcristalina y 0.25-1% de hidroxipropilmetilcelulosa y esferoide que comprende dicho nucleo con un recubrimiento de una mezcla de etilcelulosa e hidroxipropilmet | |
PA8426401A1 (es) | Formula de liberacion prolongada | |
CO4750836A1 (es) | Nuevos medicamentos y utilizacion (1-metiletil)-8-azoniabiciclo-[3.2.1]octnao y su uso en pre- paraciones medicas | |
AR002754A1 (es) | Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento | |
NO963053D0 (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
PT1121104E (pt) | Novas formulacoes orais de libertacao controlada | |
ES2176730T3 (es) | Preparacion de cinta percutanea que contiene fentanilo. | |
UA26455C2 (uk) | Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта | |
FR2675997B1 (fr) | Composition topique anti radicaux libres a base de superoxyde-dismutase et d'un derive phosphonique. | |
ES2176106B1 (es) | Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral. | |
PE17897A1 (es) | Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano | |
ES2187038T3 (es) | Glicosidos modificados, composiciones que los comprenden y procedimientos para su utilizacion. | |
ES2090066T3 (es) | Preparaciones externas que contienen agua y propionato de deprodona. | |
FI962550A0 (fi) | Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa | |
ES2177324T3 (es) | Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol. | |
BR0211188A (pt) | Composição que contém um peptìdeo e um pigmento e o uso da mesma no escurecimento da pele | |
KR890009400A (ko) | 다이클로닌 Hcl및 페놀을 함유하는 약제학적 조성물 | |
BR0210327A (pt) | Microcápsulas para proteção do hálito | |
AR003093A1 (es) | Nuevos derivados de imidazol-n-bencildioxol, su procedimiento de preparacion, su aplicacion a titulo de medicamentos, composicionesfarmaceuticas y nueva utilizacion. | |
NO20044463L (no) | Forbedret modifisert-frigjoringspreparat | |
ECSP982704A (es) | Formula de liberacion prolongada | |
MX9302986A (es) | Medicamento que contiene metrifonato y procedimiento para su preparacion | |
ECSP972046A (es) | Formula de liberacion prolongada | |
ES2149736T1 (es) | Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes. | |
PA8458401A1 (es) | Composiciones farmaceuticas que tienen actividad supresora del apetito |